FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Human Drugs

Workshop on Study Risk-Based Monitoring

FDA announces a 7/17 public workshop entitled Improving the Implementation of Risk-Based Monitoring Approaches of Clinical Investigations.

Human Drugs

Astellas Pharma sNDA Approved for Xospata

FDA approves an Astellas Pharma supplemental NDA to update the U.S. product labeling for Xospata (gilteritinib) to include final analysis data from th...

Human Drugs

FDA Working on Patient-Friendly Cancer Terms

Five FDAers working in oncology say there is a need for more patient-friendly language to use in communicating oncology drug risks and benefits.

Medical Devices

Medivis SurgicalAR Cleared for Operating Room

FDA clears a Medivis 510(k) for its SurgicalAR, an augmented reality technology platform for surgical applications and its clinical use in the operati...

Medical Devices

FDA Breakthrough Status for Resolution Bioscience Assay

FDA grants Resolution Bioscience a Breakthrough Device Designation for the Resolution HRD liquid biopsy assay, a qualitative in vitro diagnostic to de...

Human Drugs

Almirall Paying $3.5 Million on Kickback Charges

The Justice Department says Almirall is settling a whistleblower case alleging improper kickbacks to doctors for $3.5 million.

Medical Devices

Terumu Recalls Catheter Placement Devices

Terumo Medical recalls its Solopath Balloon Expandable TransFemoral System and Re-Collapsible Balloon Access System due to the potential for the tip t...

Human Drugs

Epizyme Tazemetostat NDA Filed for Epithelioid Sarcoma

Epizyme submits an NDA seeking accelerated approval of tazemetostat for treating patients with metastatic or locally advanced epithelioid sarcoma not ...

Human Drugs

Pros and Cons of Continuous Manufacturing Guidance

Support and caution is expressed by industry commenters on an FDA draft guidance on continuous manufacturing.

Human Drugs

Bioavailability Studies Guidance Comments

Two stakeholders submit comments and suggestions for an FDA draft guidance on bioavailability studies in NDAs or INDs.